<DOC>
	<DOCNO>NCT00593801</DOCNO>
	<brief_summary>Objective : To investigate whether recombinant EPO reduces need transfusion extremely low birth weight ( ELBW ) infant determine optimal time treatment . The concentration trace element antioxidant enzyme investigated patient , . Study population : 219 patient randomize 3 group</brief_summary>
	<brief_title>Erythropoietin Treatment Extremely Low Birth Weight Infants</brief_title>
	<detailed_description>Methods : Blinded , multicenter trial , ELBW infant randomize day 3 one 3 group : early EPO group ( rhEPO first week 9 week , n= 74 ) , late rhEPO group ( rhWEPO fourth week 6 week , n=74 ) , control group ( rhEPO , n= 71 ) . All infant receive enteral iron ( 3-9 mg/kg/day ) first week . The rhEPO ÃŸ dose 750 IU/kg/week . Success define transfusion hematocrit level never 30 % . The concentration trace element antioxidant enzyme investigated patient , . Clinical nutritional data record prospectively .</detailed_description>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Birth Weight</mesh_term>
	<mesh_term>Trace Elements</mesh_term>
	<mesh_term>Antioxidants</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Extremely low birth weight infant Cyanotic heart disease Major congenital malformation require surgery Gestational age &gt; 30 week Administration investigational drug pregnancy Lack parental consent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>3 Days</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>extremely low birth weight infant</keyword>
	<keyword>transfusion need</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>trace element</keyword>
	<keyword>antioxidant enzyme</keyword>
	<keyword>reduction transfusion need EPO treatment</keyword>
	<keyword>trace element antioxidant enzyme blood</keyword>
</DOC>